GLP-1 maintenance phase: what the science says vs. TikTok

What's this video probably claiming?

Based on the caption and hashtag context, @themirror_muse is likely giving a personal update on what it looks like to stay on a GLP-1 medication, such as semaglutide or tirzepatide, at a reduced or stable dose after hitting a weight loss goal. Maintenance content in the GLP-1 community typically covers dose adjustments downward, managing hunger creep, whether you can stop the drug entirely, and how to hold weight loss long-term without constantly escalating. These videos often blur personal anecdote with implicit advice, and viewers frequently interpret individual experiences as generalizable guidance. That's where it gets complicated. The creator's experience on maintenance may be genuine, but GLP-1 maintenance is one of the most misunderstood phases of treatment in the entire weight management space, and the social media version of it routinely glosses over what clinical data actually shows about what happens when doses drop or stop.

What does the science actually show?

The STEP 4 trial (Rubino et al., 2021, JAMA) is the most relevant data point here. Participants who had lost weight on semaglutide 2.4 mg and then switched to placebo regained about two-thirds of their lost weight over 48 weeks. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) replicated this with tirzepatide, showing that stopping the drug after a consolidation period led to significant weight regain compared to continuing. Both trials make one thing clear: GLP-1 maintenance is not really a phase where you stabilize and coast. For most people, the drug needs to continue to sustain the effect, because the underlying physiology, appetite dysregulation, reduced satiety signaling, energy expenditure shifts, does not resolve after weight loss. Some patients do find a lower effective dose, but that is individual variation, not a reliable rule. Dose reduction without clinical supervision is a gamble the data does not support.

Where does the social media noise diverge from clinical reality?

The GLP-1 community on TikTok tends to treat maintenance as a straightforward next chapter. You lost the weight, now you just hold it. Creators share their experience of dropping from, say, 1 mg to 0.5 mg semaglutide weekly and feeling fine for a few months, and audiences extrapolate. What they rarely see is the six-month or twelve-month follow-up where hunger returns, weight creeps back, and the person quietly restarts escalation or stops posting. There is also widespread conflation of compounded semaglutide and branded Wegovy or Ozempic in these maintenance conversations. Compounded products are not FDA-approved and have not been tested in the same trials that generated the maintenance data. Dose consistency, bioavailability, and formulation differences matter clinically. Anyone adjusting doses based on TikTok maintenance updates, rather than a prescribing clinician, is making decisions without the information needed to make them safely.

What should you actually know?

If you are on a GLP-1 and thinking about maintenance, the most honest framing is this: for most people with obesity, current evidence supports long-term or indefinite use at an effective dose, not a taper-and-stop plan. That said, individual responses vary. Some patients genuinely stabilize at lower doses. Others cannot tolerate the medication long-term due to side effects. Still others cannot afford continued use, which is a real and under-discussed issue. A 2023 analysis in Obesity Reviews (Wilding et al.) noted that cost-driven discontinuation is a leading driver of weight regain in real-world populations. Maintenance on GLP-1s is not a failure of willpower when weight comes back after stopping; it is a predictable physiological response. The conversation around it deserves more clinical honesty than most TikTok updates deliver. Talk to your prescriber before adjusting your dose based on what worked for someone else's body.